Navigation Links
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
Date:11/14/2007

OSS, Netherlands, Nov. 14 /PRNewswire/ -- Asenapine -- a fast- dissolving, sublingual tablet being developed by Organon -- was shown to be effective and well-tolerated in patients with acute schizophrenia, according to a six-week study published in the current issue of the Journal of Clinical Psychiatry. These data were previously presented at the American Psychiatric Association's (APA) annual meeting and at the annual congress of the European College of Neuropsychopharmacology's (ECNP).

In the study, asenapine 5 mg twice daily was significantly more effective than placebo in improving both positive and negative symptoms associated with schizophrenia, based on the Positive and Negative Syndrome Scale (PANSS). This difference was seen starting at the second week of treatment. Positive symptoms include hallucinations and delusions; negative symptoms include lack of emotional expression.

"Currently available atypical antipsychotic drugs like risperidone are effective at reducing hallucinations and other positive symptoms associated with schizophrenia," said Steven G. Potkin, M.D., Department of Psychiatry and Human Behavior, University of California, Irvine. "Asenapine's effect on negative symptoms, as seen in our trial, is an interesting finding."

"These results further confirm asenapine's benefits in schizophrenia, and support our continued confidence in this agent as a potential treatment for this disorder," said Dr. Willem de Laat, executive vice president, medical affairs, Organon.

About the Study

In the study, 174 patients with schizophrenia were randomized to asenapine 5 mg twice daily, risperidone 3 mg twice daily, or placebo for six weeks. Asenapine was more effective than placebo in reducing total PANSS score as well as positive symptoms and negative symptoms when measured alone. Risperidone was more effective than placebo in reducing positive symptoms.

The majority of patients (83% asenapine, 79% placebo, 90% risperidone) experienced at least one adverse event (AEs) during the study. AEs were generally mild to moderate in severity. The most commonly reported AEs (greater than or equal to 10% of the patients) were: insomnia, somnolence, nausea, anxiety, and agitation in the asenapine group; insomnia, somnolence, anxiety, agitation, and headache in the risperidone group and agitation, headache, anxiety and dizziness in the placebo group. There was no difference between the treatment groups on the incidence of extrapyramidal symptoms. Prolactin levels (greater than or equal to 2 times the laboratory upper limit of normal) were higher in the risperidone group (79%) than in the asenapine or placebo groups (9% and 2%, respectively). Asenapine-treated patients reported a lower rate of clinically significant weight gain (greater than or equal to 7%) versus risperidone-treated patients (4.3% vs. 17%; 1.9% for placebo).

The study, Efficacy and Tolerability of Asenapine in Acute Schizophrenia: A Placebo- and Risperidone-Controlled Trial, is published in the Journal of Clinical Psychiatry (2007;68:1492-1500).

About schizophrenia

Schizophrenia is a chronic, disabling brain disorder characterized by hallucinations, delusions, and disordered thinking. About 24 million people worldwide (or seven in every 1,000 adults in the population) have schizophrenia,(1) including more than two million people in the U.S.(2) and more than four million people in Europe.(3) People with schizophrenia may hear voices other people don't hear or may believe others are trying to harm them. As a result, they may become socially withdrawn, fearful, and agitated.(2)

References

(1) World Health Organization. Available online at:

http://www.who.int/mental_health/management/schizophrenia/en/.

Accessed on October 2, 2007.

(2) National Institute of Mental Health. Available online at:

http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml

(3) World Health Organization. WHO European Ministry Conference on

Mental Health. Available online at:

http://www.euro.who.int/document/MNH/emnhqa.pdf.

Accessed on October 2, 2007.

About Organon

Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel.

Safe Harbor Statement*

This press release may contain statements which address such key issues as growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals of Organon. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website http://www.akzonobel.com.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.


'/>"/>
SOURCE Organon
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
(Date:5/26/2016)... ... 26, 2016 , ... The Woodlands at John Knox Village , Florida’s ... care for living and healing, celebrated its grand opening, today. The Woodlands at John ... provided by Empowered Staff. , “This is an incredibly fulfilling time for John Knox ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... development solutions for drugs, biologics, consumer health and global clinical supply services, today ... Korea to support the company’s continued investment and strategic growth plans in the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
(Date:5/26/2016)... ... 26, 2016 , ... North Cypress Medical Center hosted its 9th ... Cypress. With the help of community partners, the event organizers raised $45,000 for the ... wounded service members and their families through health, wellness, and therapeutic support. , ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology: